Table 1

Baseline characteristics

Overall1999–2003*2004–20082009–20132014–2018
N (%)N (%)N (%)N (%)N (%)
First time PHV-implantation and first-IE-diagnosis26 604 (100.0)5634 (21.2)5650 (21.2)7016 (26.4)8304 (31.2)
Age groups
 <70 years5,327 (20)1590 (28.2)1286 (22.8)1200 (17.1)1251 (15.1)
 ≥70 years21,277 (80)4044 (71.8)4364 (77.2)5816 (82.9)7053 (84.9)
Age (median, IQR)71.7 (62.7–78.0)67.9 (58.3–74.5)70.6 (61.1–76.9)72.9 (64.4–79.1)73.9 (66.2–80.3)
Male16 778 (63.1)3433 (60.9)3617 (64.0)4418 (63.0)5310 (63.9)
Comorbidities
Cardiac implantable electronic device†2378 (8.9)177 (3.1)379 (6.7)724 (10.3)1098 (13.2)
Dialysis†349 (1.3)39 (0.7)92 (1.6)100 (1.4)118 (1.4)
Hypertension17 344 (65.2)3551 (63.0)3778 (66.9)4814 (68.6)5201 (62.6)
Diabetes3902 (14.7)478 (8.5)721 (12.8)1240 (17.7)1463 (17.6)
Acute myocardial infarction3734 (14.0)720 (12.8)831 (14.7)1053 (15.0)1130 (13.6)
Renal disease1753 (6.6)197 (3.5)304 (5.4)551 (7.9)701 (8.4)
Malignancy3657 (13.7)435 (7.7)612 (10.8)1035 (14.8)1575 (19.0)
Chronic obstructive lung disease2830 (10.6)457 (8.1)566 (10.0)834 (11.9)973 (11.7)
Atrial fibrillation/flutter8172 (30.7)1572 (27.9)1687 (29.9)2220 (31.6)2693 (32.4)
Mitral regurgitation3575 (13.4)1276 (22.6)762 (13.5)715 (10.2)822 (9.9)
Aortic stenosis21 734 (81.7)4042 (71.7)4624 (81.8)6031 (86.0)7037 (84.7)
Heart failure6911 (26.0)1685 (29.9)1422 (25.2)1797 (25.6)2007 (24.2)
Prehospital medication (within 6 months prior to admission)
Beta blockers14 474 (54.4)2867 (50.9)3265 (57.8)4039 (57.6)4303 (51.8)
Lipid lowering medication13 152 (49.4)1124 (20.0)3076 (54.4)4217 (60.1)4735 (57.0)
Anticoagulant therapy‡16 966 (63.8)4591 (81.5)4564 (80.8)3949 (56.3)3862 (46.5)
Glucose lowering medication—no insulin2890 (10.9)285 (5.1)475 (8.4)924 (13.2)1206 (14.5)
Glucose lowering medication with insulin1160 (4.4)138 (2.4)213 (3.8)371 (5.3)438 (5.3)
Corticosteroids1652 (6.2)289 (5.1)307 (5.4)477 (6.8)579 (7.0)
  • *Patients were included from the year 1996, follow-up was initiated from 1 January 1999 if they have survived and have infective endocarditis.

  • †Data only available from 2000 and onward.

  • ‡Vitamin K antagonist and novel oral anticoagulant.

  • PHV, prosthetic heart valve.